It’s panic time in Big Pharma’s boardrooms. With Trump’s return to power and RFK Jr. poised to take the helm in reshaping America’s health agencies, the pharmaceutical titans are sweating more than Fauci on election night.
“Sources tell me top five CEOs of pharmaceutical companies are holding an emergency teleconference at 1 PM.
A lawyer has confirmed that everyone is in a state of panic!”
Sources tell me top five CEOs of pharmaceutical companies are holding an emergency teleconference at 1 PM.
A lawyer has confirmed that everyone is in a state of panic!
— Jamel Holley (@jamelholley) November 6, 2024
The Gravy Train Hits the Trump Wrecking Ball
For years, Big Pharma’s business model has relied on cozying up to politicians and leveraging federal agencies to pump profits into their coffers. Biden’s administration was a golden era for them: under the guise of public health, they sold experimental vaccines like concert tickets, raking in more money in two years than most nations’ GDPs. Cheap and effective treatments were buried under red tape, and anyone who dared question the narrative was swiftly censored.
Now, the tables have turned. Trump is back, and he’s not alone. Enter Robert F. Kennedy Jr., a man who has made it his life’s mission to challenge Big Pharma and the revolving door between government agencies and industry lobbyists. His potential role in leading the charge to clean up agencies like the CDC, FDA, and NIH is giving pharma executives nightmares.
The Kennedy Factor
Kennedy’s no ordinary political appointee. He’s been a vocal critic of vaccine policies, environmental toxins, and corporate corruption. His appointment sends a clear message: it’s time to put science, integrity, and public health above profits. His focus isn’t just reform—it’s revolution. Lawsuits targeting pharmaceutical giants for negligence and harm aren’t just possible—they’re probable.
Take autism as one example. Kennedy has long argued for greater transparency and research into the potential links between vaccines and autism, a topic Big Pharma and the government have avoided like a live grenade. Now, with Kennedy in a position of influence, that grenade might just explode.
The CEOs’ Emergency Meeting
The tweet from Assemblyman Jamel Holley reveals the fear rippling through the industry. CEOs of the top five pharmaceutical companies reportedly held an emergency teleconference to strategize their survival in a new era of accountability. This level of panic before Trump even retakes the Oval Office underscores the stakes.
They’re likely discussing damage control: lobbying efforts, PR campaigns, and legal defenses. But let’s face it—this isn’t a battle they can win with a few full-page ads in the Washington Post. The Trump-Kennedy duo is about to upend decades of cronyism.
Fauci’s Reckoning
If there’s one man sweating bullets more than the pharma execs, it’s Anthony Fauci. For years, Fauci wielded enormous influence over America’s health policies, making decisions that suspiciously benefited Big Pharma. From questionable COVID-19 strategies to his handling of other epidemics, Fauci’s fingerprints are everywhere.
Kennedy has made no secret of his disdain for Fauci, calling him out for his conflicts of interest and lack of transparency. An investigation into Fauci’s dealings could reveal just how deep the corruption runs—and how much of it was at the expense of the American public.
A New Era of Health Policy
Kennedy tweeted that his mission under Trump includes cleaning up corruption, restoring evidence-based science, and tackling the chronic disease epidemic.
President Trump has asked me to do three things:
1. Clean up the corruption in our government health agencies.
2. Return those agencies to their rich tradition of gold-standard, evidence-based science.
3. Make America Healthy Again by ending the chronic disease epidemic. pic.twitter.com/WHMOsD0CiI— Robert F. Kennedy Jr (@RobertKennedyJr) November 6, 2024
This trifecta is kryptonite for an industry that has profited from the very problems it claims to solve. Chronic illness is a cash cow for Big Pharma, but a healthy population isn’t profitable. Kennedy’s vision turns that model on its head.
For years, skeptics of Big Pharma were dismissed as conspiracy theorists. Now, those “theories” are gaining traction, with real investigations and reforms on the horizon. As Trump begins his second term, the message is clear: the days of unchecked pharmaceutical power are over.
During the Financial Times Global Pharma and Biotech Summit in London on Wednesday, GSK CEO Emma Walmsley addressed the uncertainty surrounding the future of pharmaceutical operations in the U.S., according to Pharmaceutical Technology.
“The US is extremely important to GSK,” Walmsley stated. “We’re a global company, but more than half of the business is in the US, we’re very heavily invested there, with factories in many states. It is by far the most important market to bring our innovation to first.”
However, Walmsley also alluded to the need for collaboration with the incoming administration, cautiously remarking, “Let’s see what happens in terms of who is appointed into what kind of role in the administration.”
RFK Jr tweeted that the major Big Pharma executives will be invited to a dinner at the White House. At that event, I’m sure Kennedy will lay out his vision for healthcare.
Healthcare is a massive undertaking, given how large some of the companies involved are. Further, many of them have explaining to do. The article continued,
GSK, a leader in vaccines against diseases like shingles and influenza, has invested heavily in its vaccine portfolio, recently gaining approval for an RSV vaccine for older adults. Despite the company’s dominance in the vaccine market, Walmsley reminded stakeholders that “Vaccines is a big part of our business. It’s not actually the biggest part of our business, medicine is the biggest part and is growing at 20% so far this year.”
When asked about Kennedy’s “make America healthy again” mantra, Walmsley responded, “Actually, making America healthy again is a really good idea.” She pointed to concerning health trends in the U.S., where the average life expectancy lags behind other developed countries by four years.
Donald Trump has experts in multiple areas. Watching competent people do their jobs will be a refreshing change from the previous administration. I wouldn’t be surprised if the Big Pharma execs all brought their paper shredders to that conclave.
